MicrofluidX welcomes new board members and scientific advisor

MicrofluidX, a UK-based developer of technologies that streamline the development and deployment of cell and gene therapies, today announces the appointment of two new board members and an additional scientific advisor to support the company as it progresses towards market launch of its unified development and manufacturing platform, the Cyto EngineTM

The addition of these three distinguished leaders in their respective fields, brings a wealth of expertise to the MicrofluidX team, providing insight into the needs of cell and gene therapy manufacturers as well as extensive experience in the development of innovative tools and technologies to help meet the needs of this rapidly growing sector.

The company welcomes:

Tim Fell - Chair
With a 30+ year career in life sciences technology innovation Tim assumes the role of Board Chair. His proven track record in converting innovation into products and building early stage companies into successful commercial organizations will be instrumental in supporting MicrofluidX through its next phase of technology development and commercialization.

Joseph Gentile - Non-Executive Director
Joseph’s wealth of experience building innovative tools and technology companies in the cell and gene therapy and life sciences sectors provides a tremendous addition to the MicrofluidX board. Based in the US, his support, strategic direction, and guidance in this high-value region will be invaluable as the technology progresses to market entry.

Steven A Feldman - Scientific Advisor
As Site Head and Scientific Director for Stanford’s Laboratory for Cell and Gene Medicine and its GMP Manufacturing Facility, Steven is an internationally recognized expert in the development of cell and gene therapies. As a Scientific Advisor, he will provide key guidance in developing and refining the company's cutting-edge technologies.

CEO of MicrofluidX Antoine Espinet says “We are immensely proud to welcome Tim, Joseph and Steven to the MicrofluidX team. Their experience and insights into developing technologies and building companies, as well as the needs of the Cell and Gene Therapy community will be invaluable as we take the Cyto EngineTM from prototype to product.”

 

More news and updates 

ImmuONE is celebrating triple triumph at the inspiring herts awards 2024

We’re proud to announce that ImmuONE took home the prestigious award for ‘Business of the Year – North Herts’, which was awarded to us for consistent growth, robust financial performance, and unwavering commitment to staff and innovation. From the pool of winners, there was also a special recognition category which honoured ImmuONE with the ‘Inspiring Business of the Year’ award for making the biggest innovation in Hertfordshire.

Cryoport systems officially launches global supply chain hub in Stevenage

Cryoport, Inc a global leader in innovative supply chain solutions for the cell and gene therapy industry, is thrilled to announce the official launch of the Cryoport Systems state-of-the-art Global Supply Chain Hub in Stevenage, U.K.

Microbiotica to present positive update on manufacturing progress of its live biotherapeutic products

Microbiotica, a biopharma company developing a pipeline of orally-delivered precision microbiome medicines announces that Adam Wilkinson, its Vice President of Pre-Clinical Development, will present an overview of the company’s successful product manufacturing campaigns ahead of its forthcoming melanoma and ulcerative colitis clinical studies at the 9th Microbiome Movement Drug Development Summit, on 11 July, in Boston, USA, together with Claire Derlot, CBO from its GMP manufacturing partner Biose Industrie.

Milner Institute celebrates success of 2024 Pitch Day and therapeutics symposium

The Milner Therapeutics Institute were delighted to host two sell-out events in Cambridge that brought academics, investors, pharma and biotech companies together.

Moa harvests global deal for new herbicide

Moa Technology has signed a major research and commercial agreement with Australian ag giant Nufarm. The deal will see Moa receiving receive upfront payments, milestone development payments and royalties in return for Nufarm gaining exclusive access to a product in one of Moa's breakthrough novel mode of action areas.

Myricx Bio announces £90 million Series A financing to advance its novel NMTi-ADC therapeutics into clinical development

£90 million ($114 million) series A co-led by new leading life science investors Novo Holdings and Abingworth; additional new investors British Patient Capital, Cancer Research Horizons and Lilly participated alongside founding investors Brandon Capital and Sofinnova Partners.

NCIMB Ltd kicks off innovative enzyme technology development project

Aberdeen-based biotechnology company NCIMB has kicked-off a new research project to demonstrate novel enzyme technology with an exciting array of potential applications in the pharmaceutical, food & drink and environmental sectors.

Promising results from cardiac fibrosis studies with MRX1

Ananda Developments PLC, a clinical-stage life sciences company focused on the development of CBD based therapies for the treatment of a range of complex inflammatory pain conditions, is delighted to share promising results from recent preclinical studies investigating the efficacy of MRX1 (Patent Pending) in treating cardiac fibrosis and heart failure with preserved ejection fraction (HFpEF).

Valneva Scotland appoints science communications consultancy, Perceptive Communicators

Glasgow-based specialist communications consultancy, Perceptive Communicators, has announced its appointment to provide strategic communications services for Valneva Scotland.

Coulter Partners places Head of Sales North America at Pelago Bioscience

Coulter Partners recently partnered with Pelago Bioscience and is pleased to announce the placement of Brian Jarecki, PhD as Head of Sales North America.

 

More within